Par Pharmaceutical Companies Net Income: 21.93M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRX Net Income Rankings
| Overall | 70th percentile | 1343 of 4597 |
| Sector | 82nd percentile | 92 of 525 in Healthcare |
| Industry | 69th percentile | 4 of 13 in Drugs - Generic |
PRX Net Income Range, Past 5 Years
| Minimum | -55.82M | Dec 2005 |
| Maximum | 38.74M | Sep 2003 |
| Average | 3.71M |
About Net Income
Net income is what remains of a company's revenue after subtracting all costs. It is also referred to as net profit, earnings, or the bottom line.
Learn More
You may also be interested in these PRX related companies
PRX News
Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc.
Feb 06, 12:01PM Business Wire
Feb 06, 12:01PM Business Wire
$PRX New 52 Week High - Crossed daily highs resistance. Next resistance 39.00 from 1/4/2011.
about 9 days ago by TradeIdeasQuant
about 9 days ago by TradeIdeasQuant
Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012
Jan 31, 9:00AM PR Newswire
Jan 31, 9:00AM PR Newswire
I don't think the pricing fixing case against $PRX is going to have much of an effect. Last I checked they have about 50 other products..
about 29 days ago by bradloncar
about 29 days ago by bradloncar
UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Shaping Up To Be Strong Growth Story
Jan 09, 10:51AM Street Insider
Jan 09, 10:51AM Street Insider
Needham & Company: Thoughts Heading Into Par Pharmaceutical's (PRX) January 6, Analyst Day; Generics Take Center Stage
Jan 06, 11:20AM Street Insider
Jan 06, 11:20AM Street Insider
Listen to $PRX Par Pharmaceutical Companies Investor Day - live at 09:00 AM, ondemand after - http://stks.co/1nwc
about 37 days ago by earningscast
about 37 days ago by earningscast
Leerink Swann Remains Positive on Shares of Par Pharmaceutical (PRX) Following Meeting With Management
Nov 30, 10:59AM Street Insider
Nov 30, 10:59AM Street Insider
Par Pharma promotes Thomas Haughey to President and Paul Campanell as COO
Nov 22, 8:36AM FlyOnTheWall
Nov 22, 8:36AM FlyOnTheWall
Magic Formula Links for 8/24/2011 $AMAT $GTAT $MHP $PRX $GME http://stks.co/1Bx
about 171 days ago by MagicDiligence
about 171 days ago by MagicDiligence
Intellipharmaceutics and Par Expand Development and Commercialization Agreement $IPCI $PRX http://stks.co/PK
about 178 days ago by IPCI
about 178 days ago by IPCI
$PRX http://chart.ly/jeylvad it was the gap up and close back over the 20-day MA so maybe over $25 or $25.40 on good volume
about 261 days ago by StockTiger
about 261 days ago by StockTiger
Par Pharma - Buried in the Generic Drugs Battlefield $PRX $TEVA $WPI $MYL $NVS http://stk.ly/kB9i9C
about 276 days ago by MagicDiligence
about 276 days ago by MagicDiligence
$PRX $34.97 HAUGHEY THOMAS officer (EVP, CAO, General Counsel) S 198,860 @ $34.76 amnt $6,913,347 proc'd ($40,803) 5/10/2011
about 276 days ago by canarionyc
about 276 days ago by canarionyc
$PRX http://chart.ly/wp6ct45 from watch list - not a big move from today's trigger but volume good at 167% of ave full day
about 279 days ago by StockTiger
about 279 days ago by StockTiger
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRX | 36.55 | -0.50 | -1.35% | 1.33B |
| ADVS | 27.23 | -0.44 | -1.59% | 1.38B |
| ABC | 38.60 | -0.37 | -0.95% | 9.97B |
| MOV | 18.85 | 0.00 | 0.00% | 343.64M |
| NOK | 4.96 | -0.11 | -2.17% | 18.58B |
| CLS | 8.68 | -0.02 | -0.23% | 1.71B |
| BWLD | 85.72 | 1.08 | 1.28% | 1.57B |
| PTEK | 0.62 | -0.01 | -0.90% | 4.30M |
| PVH | 81.30 | 0.03 | 0.04% | 5.49B |
| GIB | 20.39 | -0.09 | -0.44% | 4.62B |
